Quick Answer
Anika Therapeutics, Inc. reported Long-Term Debt of $8.00 million for fiscal year 2012.
Anika Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2012 | $8.00M | -16.7% |
| 2011 | $9.60M | -14.3% |
| 2010 | $11.20M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $25.00M | — | -50.0% |
| June 30, 2020 | $50.00M | — | — |
| December 31, 2019 | $0.00 | — | -100.0% |
| September 30, 2013 | $6.80M | -19.0% | -5.6% |
| June 30, 2013 | $7.20M | -18.2% | -5.3% |
| March 31, 2013 | $7.60M | -17.4% | -5.0% |
| December 31, 2012 | $8.00M | -16.7% | -4.8% |
| September 30, 2012 | $8.40M | -16.0% | -4.5% |
- Anika Therapeutics, Inc. showed a decrease of -16.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2012 period, Anika Therapeutics, Inc.’s long-term debt has declined by 28.6% (from $11.20 million to $8.00 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2013 report (Form 10-K), filed with the SEC on March 13, 2014.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: